Prepared for
Pharma
Hero Finding
The majority of oncologists named the Established Doublet as their preferred backbone for the novel agent: the combination's efficacy profile and physician familiarity made it the dominant choice across all markets.
In both forced-choice and 100-point allocation exercises, the Established Doublet emerged as the clear primary backbone, leading the Newer Doublet and Monotherapy by a wide margin in both single-select agreement and allocation share. The alternate-dose configuration of the Established Doublet (lower induction dose with reversed sequencing) further strengthened the backbone: a majority of oncologists preferred the alternate dose over standard, and the projected reduction in discontinuation risk was cited as the primary driver.
Majority
Named the Established Doublet as preferred clinical backbone (single-select)
Majority
Would prescribe within 6 months of Established Doublet backbone approval
Majority
Prefer alternate-dose Established Doublet over standard dose
Study Design
N=110 oncologists across 4 markets · AI-moderated 25-minute interviews · treatment landscape mapping and pipeline concept testing.
The sample was designed to span the full first-line advanced-oncology decision-making population across North American and European markets, with sufficient country representation to surface geography-specific prescribing patterns and adoption barriers.
Sample segmentation
Medical Oncology · 73
General Oncology · 33
Subspecialty · 4
Interview guide · core topics
- Current treatment decision-making: factors, patient segmentation, and therapy selection by molecular subtype
- Performance ratings across 9 attributes for existing first-line regimens (Established Doublet, Newer Doublet, Monotherapy)
- Alternate-dose Established Doublet: awareness, usage, patient selection criteria, and prescriber assessment
- Novel agent concept reception: MOA assessment, unmet need fit, and clinical differentiation
- Backbone preference: forced-choice and 100-point allocation across three combination scenarios
- Market share simulation: 100-point treatment allocation before and after novel agent availability
- Adoption timeline modeling: prescribing intent, immediate vs. delayed adoption, and resistance drivers
- Country-level variations: regional prescribing patterns and regulatory context differences
Recruit criteria
- Practicing oncologist treating the target advanced indication
- Minimum 10 first-line patients in past 12 months
- 3-30 years post-fellowship with majority direct patient care time
- Board-certified or equivalent; active prescriber across the 4 markets
Key Findings
What shaped the clinical trial backbone recommendation.
Five signals drove the medical affairs team's view of backbone selection, adoption dynamics, and the geography-specific go-to-market strategy.
Majority
Established Doublet as preferred backbone (single-select)
Majority
Would prescribe within 6 months (Established Doublet backbone)
Majority
Prefer alternate dose over standard configuration
Majority
Would transition immediately to first-line if initially approved second-line
14 days
Study design to final report
01
The Established Doublet is the dominant backbone, leading the Newer Doublet and Monotherapy by a wide margin in both single-select preference and allocation share.
The combination's efficacy leadership and broad physician familiarity across all markets made it the default backbone choice. Academic oncologists drove the Established Doublet preference more strongly (immediate adoption nearly twice the community rate), while community oncologists were more monotherapy-anchored for tolerability-limited patients. The Newer Doublet attracted a meaningful minority cohort, concentrated in physicians managing older or more comorbid patients where tolerability is the dominant selection criterion.
02
The alternate-dose configuration is the differentiating factor: a majority prefer it over standard dose, with a projected reduction in treatment discontinuation.
Alternate dosing (lower induction dose with reversed sequencing) has already seen meaningful uptake in North America, with materially lower adoption in Europe. In the novel agent context, a majority of oncologists prefer the alternate-dose combination over standard, driven by the projected reduction in adverse-event-related discontinuation. About half would change practice based on alternate-dose data alone. The clinical trial design implication: an alternate-dose arm alongside standard dose in Phase 3 would address the tolerability question that is the primary adoption barrier.
03
Adoption velocity is high: roughly a third would prescribe immediately and a majority within 6 months, with very low rejection.
The Monotherapy backbone drew a rejection rate several times higher than the Established Doublet, primarily because monotherapy-loyal oncologists see monotherapy as already efficacious for their patient populations and view combination therapy as adding toxicity without sufficient benefit. The Established Doublet backbone's near-zero rejection rate reflects near-universal prescriber openness for the right patient. For first-line adoption, the primary delay factor is demand for subgroup data, not efficacy skepticism.
04
North American and European prescribing patterns diverge significantly across multiple dimensions.
Alternate dosing awareness and use is concentrated in North America. Comprehensive molecular panel testing is far more common in North America than Europe. Targeted-therapy first for biomarker-positive patients is more common in Europe. These differences require country-specific go-to-market strategies: a North American launch can lead with alternate-dose messaging; European markets need separate tolerability and evidence framing.
05
Second-line approval is a viable entry pathway: most oncologists would use the novel agent in 2L if initially approved there, and the majority would immediately transition to 1L once available.
The 2L-to-1L transition pathway is strongly supported: the majority would not wait for additional evidence before moving to first-line once the label allows it. Superior survival is the cited transition driver for a plurality of respondents. This creates a launch sequencing option with lower evidentiary bar for 2L entry and rapid 1L conversion, reducing time-to-commercial-milestone vs. a pure 1L approval strategy.
“This is the strongest survival benefit I have seen in this disease. Combined with the tolerability advantage of the alternate dose, that combination changes how I think about first-line treatment for fit patients with high disease burden.”— Oncologist, Academic Medical Center
Crosstab · Adoption Timeline by Backbone
The Monotherapy backbone carries a rejection rate several times higher than the Established Doublet: backbone selection is a de facto market access decision.
Adoption timeline distribution across N=110 oncologists for each backbone configuration. The 'will never prescribe' row shows the structural market access gap between backbone choices.
| Established Doublet (index) | Newer Doublet (index) | Monotherapy (index) | |
|---|---|---|---|
| Prescribe immediately | 37 | 32 | 25 |
| Cumulative within 1-2 months | 58 | 55 | 53 |
| Cumulative within 6 months | 85 | 87 | 79 |
| Cumulative within 12 months | 100 | 100 | 100 |
| Will never prescribe | 2 | 6 | 14 |
Indexed · blinded valuesN=110 · all four marketsEstablished Doublet near-zero rejection vs. Monotherapy multi-fold rejectionMajority six-month adoption (Established Doublet backbone)
Voice of Customer
How oncologists described their prescribing logic and their reaction to the novel agent.
Verbatims from AI-moderated interviews across multiple markets, selected to represent the range of treatment philosophies and backbone reactions.
Efficacy-First · Established Doublet Logic
“I prefer the Established Doublet in nearly all first-line patients unless there are underlying comorbidities. The combination offers the highest efficacy endpoints across response rate, duration of response, and overall survival. That is the baseline.”
— Oncologist, Community Practice
Alternate Dose · Tolerability Advantage
“Severe adverse events are markedly lower with the alternate dose, which is attractive. Given equivalent efficacy and superior safety, including lower discontinuation, all future prescribing would be alternate dose in the triplet.”
— Oncologist, Academic Medical Center
Newer Doublet Backbone · Tolerability Window
“The novel agent plus the Newer Doublet is a clear favorite for me because it achieves the best therapeutic window: outstanding efficacy and best possible tolerability. For older patients or those with multiple comorbidities, tolerability becomes especially important.”
— Oncologist, Academic Medical Center
Adoption Velocity · Survival as Primary Driver
“Yes, we would use it right away. If it is really improving how long people survive, we would not defer it. Improvement in overall survival is what drives a practice change.”
— Oncologist, Academic Medical Center
Evidence Threshold
“I need concrete clinical data, ideally from large randomized trials published in peer-reviewed journals, with all clinically relevant data provided on survival and side effects. The overall signal is positive, but the evidence threshold before changing practice is high.”
— Oncologist, Academic Medical Center
Counter-intuitive
Backbone selection is a de facto market access decision: Monotherapy has many times the rejection rate of the Established Doublet despite broader physician familiarity.
The intuitive assumption is that Monotherapy, as the most widely prescribed and familiar agent class, would produce the broadest market access for a novel triplet combination. The data inverted that logic. Physicians who are anchored to monotherapy view it as already efficacious for their patient populations and reject combination therapy as adding toxicity without proportional benefit. The elevated rejection rate for the Monotherapy backbone vs. the near-zero rejection for the Established Doublet is not a familiarity advantage; it is a loyalty barrier. The Established Doublet backbone, despite its higher toxicity profile, attracts physician populations who are already managing that toxicity and who see the novel agent as an upgrade to a regimen they are already using.
Strategic Implications
Three clinical and commercial moves from the research.
What the medical affairs team took into Phase 3 design planning and go-to-market strategy, grounded in the prescriber preference data and adoption modeling.
01
Design Phase 3 with the Established Doublet as the primary backbone, with an alternate-dose arm alongside standard dose.
The clear majority single-select preference and dominant allocation share make the Established Doublet the unambiguous first-choice backbone for clinical trial design. Including an alternate-dose arm addresses the tolerability barrier that is the primary adoption concern: most oncologists prefer alternate dose over standard, and the projected discontinuation reduction is cited as the differentiating factor by the highest-volume prescribers.
02
Build a North America-specific go-to-market strategy around alternate-dose messaging; plan separate European evidence packages.
The North America vs. Europe prescribing divergence is substantial enough to require country-specific commercial strategies. North American oncologists are already substantially alternate-dose adopters: the commercial narrative there is a natural upgrade from a familiar regimen. European markets vary widely in alternate-dose adoption and need separate tolerability evidence and guideline-based framing. Some European oncologists prioritize patient preference data more than any other market; others face the highest external prescribing constraints.
03
Evaluate a second-line entry strategy as a commercial acceleration pathway.
Most oncologists would use the novel agent in second line if approved there first, and a majority would immediately transition to first line without waiting for additional evidence once the 1L label is available. The 2L-to-1L pathway reduces the evidentiary bar for the initial regulatory package while preserving rapid 1L capture. The primary condition: the 1L data must demonstrate superior overall survival, which a plurality of oncologists cite as the specific evidence trigger for immediate 1L adoption.
Success criteria · 12 months
- Phase 3 trial design includes alternate-dose arm alongside standard Established Doublet backbone
- Subgroup data (by performance status, disease burden, biomarker status) available at interim readout
- Country-specific commercial messaging developed for all 4 launch markets
Risk register
| Alternate-dose evidence insufficient at launch | HIGH |
| Ex-NA guideline barriers (HTA bodies) | HIGH |
| Established Doublet toxicity driving Newer Doublet shift | MED |
| 2L approval timeline delay | MED |